Health Care • Biotechnology: Pharmaceutical Preparations
$24.21 ▲ +1.71
(+7.60%)
MKT CAP: $1.16B • VOL: 3.10M
52W L $22 52W H $53
ROARABLE / RQD
D- • 43/100
PIOTROSKI
2 / 9
RAPP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$125.1M | -$83.1M | -$36.2M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$111.5M | -$78.3M | -$34.8M |
| EBITDA (Normalized) | -$124.6M | -$81.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$87.5M | -$64.8M | -$27.2M |
| Capital Expenditures (CapEx) | $616.0K | $2.4M | — |
| Free Cash Flow (FCF) | -$88.1M | -$67.2M | -$27.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -22.9% | -26.4% | — |
| Cash & Short-Term Equivalents | $52.6M | $56.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $484.7M | $305.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RAPP.